This program is designed for hematologists/oncologists, dermatologists, researchers, physician assistants, nurses and students.
At the conclusion of this activity, attendees should be better able to:
- Describe new screening, diagnostic, and surveillance techniques, as well as the follow-up of patients with early melanoma using the latest technologies.
- State the role of complete node dissections for microscopic nodal disease based on current evidence that assesses the clinical utility of sentinel node mapping in the management of malignant melanoma.
- Assess the current state of adjuvant therapy and options that may be available in the future.
- Compare the advantages and limitations of intralesional, locoregional and systemic interventions for treatment of advanced cutaneous malignancies.
- Assess unique clinical situations such as brain metastases, Merkel cell carcinoma, mucosal melanoma, and uveal melanoma and determine appropriate treatment approaches.
- Examine recent evidence about basal cell carcinomas and the management of cutaneous t-cell lymphomas and aggressive squamous cell carcinomas.
- Review potential benefits and adverse effects of emerging therapeutic agents for the treatment of primary cutaneous malignancies.
- Obtain an understanding of the role of currently available and potential future applications of immunotherapy and targeted therapy for advanced melanoma.
- Analyze outcomes from investigative clinical trials that involve the use of adjuvant therapy and novel biologics for the treatment of high risk melanoma.
- Determine how to best utilize the various biomarkers and molecular testing to determine prognosis and optimize care for patients with melanoma.
- Evaluate the potential positive impact that interdisciplinary approaches to melanoma treatment may have on patient outcomes.
- Analyze potential algorithms for the treatment of advanced melanomas, using newly approved agents, to assist in therapeutic decision making.
- Examine emerging clinical challenges regarding melanoma care.
- Assess the latest clinical evidence regarding the use of immune checkpoint inhibitors as both mono and combination therapy for the management of advanced melanoma.
- Review common immune-related adverse events as well as a multidisciplinary approach for their identification and management.
|Meeting organized by
|This continuing medical
education activity is provided by
|Official media partnership with